Related Experiment Video
Updated: Jun 20, 2026

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
Published on: April 14, 2016
[Effectiveness of oral tramadol hydrochloride for chronic non-malignant pain]
Masaki Kitahara1, Keiko Kojima, Maki Hanada
1Clinical Pain Service, Jikei University Hospital, Tokyo 105-8471.
Background:
Tramadol hydrochloride is a centrally acting analgesic agent with two distinct mechanisms of action, a weak opioid agonist and an inhibitor of monoamine neurotransmitter reuptake, which produces significant analgesic effect synergistically. Though tramadol was approved in 1978 in Japan, it has rarely been used in clinical settings compared to foreign countries, e.g. Germany and USA. The aim of this study is to investigate effectiveness of oral tramadol for chronic non-malignant pain in Japan.
Methods:
Tramadol was orally administered to patients with refractory non-malignant pain. Effects and adverse effects of tramadol were assessed about one month after the start of the administration.
Results:
Out of 17 patients using tramadol daily, tramadol was found to be significantly effective in 4 patients (23.5%) and moderately effective in 8 patients (47.1%) from the viewpoint of pain relief as well as improvement of activities of daily livings. Side effects were reported by 7 patients (41.2%), which included nausea, constipation, and dizziness, but none of the side effects were serious.
Conclusions:
Tramadol is a useful option to treat non-malignant chronic pain, especially considering its very low abuse potential and a more acceptable side effect profile compared to non-steroidal anti-inflammatory drugs and opioids.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Opioid Analgesics: Morphine and Other Natural Cogeners
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Oral Drug Delivery Systems: Continuous-Release Systems